Biolog Device Affiliate Biomedipharm Obtains Russian Patent for 'High-Purity PDRN Raw Material Extraction'

[Asia Economy Reporter Jang Hyowon] BioLog Device, a KOSDAQ company, announced on the 25th that it has obtained a Russian patent related to high-purity PDRN raw material extraction, developed in collaboration with Biomedipharm Fisheries Company (hereinafter Biomedipharm).

This is the first overseas patent obtained just one year after filing the domestic patent for the revolutionary technology in high-purity PDRN extraction and yield, titled "Method for Extracting High-Purity PDRN from Salmon Testes."

In the future, additional patents are planned to be filed for ▲ technology to quantitatively secure salmon DNA materials by field using gene recombination ▲ identification and utilization of function-customized salmon DNA ▲ extraction of salmon double-stranded DNA using a non-alcohol extraction method.

A Biomedipharm official stated, "We are currently filing the same patent in the United States, Europe, Japan, and China," adding, "The acquisition of the Russian patent marks a significant milestone, providing a new turning point for international patent registration."

According to regenerative medicine market analysis data from NICE Evaluation Information, the market size including PDRN recorded $4.47 billion this year and is expected to grow by approximately 71.8% to reach $7.68 billion in 2024. The market leader in this field, PharmaResearch Group, has a market capitalization exceeding 900 billion KRW.

Gwon Onam, head of Biomedipharm's research institute, said, "We will continue to collaborate with related industries through various national research projects and gain recognition for the quality of our products."